NCT00228982View on ClinicalTrials.gov

Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections

PHASE3CompletedINTERVENTIONAL
Enrollment

784

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions
Skin Diseases, InfectiousSkin Diseases, BacterialStaphylococcal Skin Infections
Interventions
DRUG

Ceftobiprole medocaril

DRUG

Vancomycin

Sponsors
All Listed Sponsors
lead

Basilea Pharmaceutica

INDUSTRY

NCT00228982 - Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections | Biotech Hunter | Biotech Hunter